丹参酮ⅡA磺酸钠注射液治疗老年肺源性心脏病的临床效果

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (367 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Sodium Tanshinone ⅡA Sulfonate Injection in the treatment of senile pulmonary heart disease. Methods Eighty-six cases of elderly patients with acute stage of pulmonary heart disease treated in Beijing Luhe Hospital, Capital Medical University from June 2013 to June 2015 were selected and divided into control group and observation group by random number table method, with 43 cases in each group. Both groups were given conventional treatment, on basis of which, the observation group was added with Sodium Tanshinone ⅡA Sulfonate Injection, intravenous drip. The clinical effect of the two groups was observed, the indexes of hemorheology, arterial blood gas analysis, pulmonary artery systolic pressure of the two groups before and after treatment were compared, the adverse reactions of the two groups during the course of treatment were recorded. Results The total effective rate of observation group (88.37%) was higher than that of control group (76.74%), the difference was statistically significant (P ＜ 0.05). After treatment, the indexes of hemorheology (whole high blood viscosity, whole low blood viscosity, plasma viscosity, hematocrit, red cell assembling index, platelet aggregation rate, fibrinogen) in the two groups were all lower than those before treatment, the differences were statistically significant (P ＜ 0.05); after treatment, the indexes of hemorheology above in the observation group were all lower than those of control group, the differences were statistically significant (P ＜ 0.05). Compared with before treatment, the PaO2 of the two groups after treatment were increased, PaCO2 and pulmonary artery systolic pressure were decreased, the differences were statistically significant (P ＜ 0.05). After treatment, the PaO2 of observation group was higher than that of control group, the PaCO2 and pulmonary artery systolic pressure were lower than those of control group, the differences were statistically significant (P ＜ 0.05). Both groups had no obvious adverse reactions during the treatment. Conclusion Sodium Tanshinone ⅡA Sulfonate Injection in the treatment of senile pulmonary heart disease has significant effects, which can reduce the clinical signs and symptoms, improve the cardiac function and the states of hemorheology and pulmonary arterial hypertension, and the safety is high, which is worthy of clinical promotion and application.

Key words： Pulmonary heart disease Sodium Tanshinone ⅡA Sulfonate Injection Elderly Pulmonary arterial hypertension Hemorheology

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	QIN Hongjie1 CHEN Xinguang2

Cite this article:

QIN Hongjie1 CHEN Xinguang2. Clinical effect of Sodium Tanshinone ⅡA Sulfonate Injection in the treatment of senile pulmonary heart disease[J]. 中国医药导报, 2017, 14(26): 130-133.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I26/130

[1] 王新荣，赵苏.丹参酮ⅡA磺酸钠对肺心病患者血流变及血脂的影响[J].中国生化药物杂志，2011，32（3）：237-238.
[2] 柳海琛，柳海环.18例丹参酮ⅡA磺酸钠注射液不良反应的临床特点分析[J].中国中西医结合杂志，2013，33（9）：1287-1289.
[3] 熊明媚.丹参酮ⅡA磺酸钠联合阿托伐他汀治疗慢性阻塞性肺疾病合并肺动脉高压的疗效[J].中国老年学杂志，2016，36（9）：2193-2195. DOI：10.3969/j.issn.1005-9202. 2016.09.067.
[4] 江倩，陈豫钦，陈秀庆，等.丹参酮ⅡA磺酸钠抑制野百合碱致肺动脉高压大鼠肺动脉平滑肌过氧化物酶体增殖物激活受体γ表达的研究[J].中华结核和呼吸杂志，2014，37（5）：360-364. DOI：10.3760/cma.j.issn.1001-0939. 2014.05.012.
[5] 朱晓多，邹晖.丹参酮ⅡA磺酸钠注射液对冠心病合并高尿酸血症患者血尿酸、CRP及血液流变学变化的影响[J].中国中医药科技，2013，20（4）：334-335. DOI：10.3969/j.issn.1005-7072.2013.04.004.
[6] 王洪锐，李东，翁浩聪，等.丹参酮ⅡA 磺酸钠注射液不良反应的流行病学特征研究[J].中国药业，2014，23（14）：43-45.
[7] 赵一举，程显声.第三届全国肺心病心功能会议纪要[J].中华结核和呼吸杂志，1990，13（5）：307-308.
[8] 董承琅，内寿淇，陈灏珠.实用心脏病学[M].3版.上海：上海科学技术出版社，1996.
[9] 刘印红，张勇，张扬，等.丹参酮ⅡA磺酸钠对高龄肺源性心脏病患者血流动力学、心功能的影响[J].海南医学院学报，2016，22（1）：24-26. DOI：10.13210/j.cnki.jhmu.20150918.013.
[10] 王俊伟，罗莉丽.丹参酮ⅡA磺酸钠注射液联合米力龙对慢性肺心病失代偿期患者疗效及血液流变学的影响[J].实用临床医药杂志，2015，19（15）：5-7，22. DOI：10.7619/jcmp.201515002.
[11] 刘曼玲，李志超，董明清，等.丹参酮-ⅡA磺酸钠对慢性低氧性肺动脉高压大鼠的治疗作用[J].中国药理学通报，2008，24（6）：723-726. DOI：10.3321/j.issn：1001-1978.2008.06.007.
[12] 王静，杨宝江，常银竹，等.参附注射液联合丹参酮ⅡA磺酸钠注射液治疗慢性阻塞性肺疾病急性加重期[J].吉林中医药，2015，35（7）：696-700.
[13] 郭欣然，翁育清，谢灿茂，等.肺心病血栓前状态及抗凝干预疗效分析[J].中国实用内科杂志，2002，22（8）：479-480. DOI：10.3969/j.issn.1005-2194.2002.08.016.
[14] 邢鹏程，马可，李利娟，等.比索洛尔治疗老年慢性阻塞性肺病急性加重并肺心病患者的疗效及对心功能、hs-CRP、NT-proBNP水平的影响[J].中国老年学杂志，2015，35（20）：5845-5847.
[15] 王政权，董路兵，李刚，等.NT-proBNP动态改变在云南地区汉族慢性阻塞性肺疾病合并肺源性心脏病患者诊断及长期预后判断中的意义[J].中国临床医学，2015， 22（5）：616-620.
[16] 雷应军，胡振红，刘海潮，等.无创正压通气对COPD合并肺源性心脏病急性加重期患者疗效和血气、炎性指标的影响[J].疑难病杂志，2016，15（3）：233-235，240.
[17] 乔人立.重新认识慢性阻塞性肺疾病与肺源性心脏病[J].中华结核和呼吸杂志，2011，34（4）：246-248.
[18] 王建雄，谢言秋，彭沪，等.丹参酮ⅡA磺酸钠注射液治疗老年肺源性心脏病患者的临床观察[J].中华老年心脑血管病杂志，2015，17（5）：532-533. DOI：10.3969/j.issn.1009-0126.2015.05.026.
[19] 罗辉遇，李奕华，胡燕怡，等.肺源性心脏病急性加重期凝血状态与动脉血气的相关性及预后影响分析[J].广东医学，2016，37（2）：221-223.
[20] 张莹莹，吕晓红，丁会，等.老年慢性肺源性心脏病心力衰竭急性加重期患者血清降钙素原与B型利钠肽水平变化[J].中国老年学杂志，2014，34（7）：1746-1747.DOI：10.3969/j.issn.1005-9202.2014.07.006.
[21] 李春陵，朱静雯，王里，等.丹参酮ⅡA磺酸钠对慢性阻塞性肺疾病气道重塑大鼠PPARγ、NF-κB的影响研究[J].贵州医药，2016，40（5）：466-468. DOI：10.3969/j.issn.1000-744X.2016.05.006.
[22] 孔爱华.环磷腺苷葡胺联合丹参酮ⅡA磺酸钠治疗肺心病的临床疗效[J].临床肺科杂志，2015，20（6）：1112-1114. DOI：10.3969/j.issn.1009-6663.2015.06.046.